Skip to content

Pharma lobby ousts 22 drug makers amid price debate

May 9, 2017
  • Changes require minimum spending level for R&D activities
  • Smaller companies disappeared from website after changes

Pharmaceutical Research and Manufacturers of America, or PhRMA, will require members spend $200 million a year on research and development, based on a three-year average, and also show their R&D spending amounts to at least 10 percent of their global sales. The changes, reported by Bloomberg Sunday, follow a three-month review that has already seen several member companies leave the powerful trade group.

“Being a member of PhRMA means being committed to doing the time-intensive, scientifically sound research it takes to bring bold new advances in treatments and cures to patients,” said Joaquin Duato, PhRMA chairman and Johnson & Johnson’s worldwide chairman for pharmaceuticals, in a statement announcing the changes.

The changes also eliminate “research associate” members from group. BioMarin Pharmaceutical Inc. and Aerie Pharmaceuticals Inc., which were research associates, no longer appear on PhRMA’s web page of member companies.

In total, PhRMA’s website now lists about three dozen companies. A spokeswoman for BioMarin didn’t immediately respond to a request for comment.


From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: